Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis.

ABSTRACT:

Background

Comorbid rheumatoid arthritis (RA) is known to be associated with excess mortality in patients with bronchiectasis. However, whether excess mortality is affected by RA seropositivity and is altered by using disease-modifying anti-rheumatic drugs (DMARDs) remains unknown.

Objectives

To assess the association between comorbid RA and mortality in participants with bronchiectasis, plus the impacts of seropositivity and DMARDs on this association.

Design

A retrospective cohort study.

Methods

Mortality rates were compared between participants with bronchiectasis-RA overlap syndrome (BROS) (n = 3355; 2632 seropositive RA (SPRA) and 723 seronegative RA (SNRA)) and 1:5 age- and sex-matched participants with bronchiectasis only (n = 16,240) who w

SUBMITTER: Choi H 

PROVIDER: S-EPMC12329186 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature